|
| |
Valeant Pharmaceuticals InternationalValeant Pharmaceuticals International (NYSE: VRX) is a global, science-based specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products, primarily in the areas of neurology, infectious disease and dermatology. Through its global infrastructure, Valeant develops and commercializes important treatments for patients worldwide. Valeant has made rapid strides under a new management team with a strategic vision and renewed focus on its specialty pharmaceuticals business. The company has implemented major changes in the areas of product management, business development, research and development, corporate governance and supply chain operations.
In 2005, Valeant total revenues were $823 million, including product sales of $731 million that were generated through 430 products and more than 2,300 SKUs. Based in Aliso Viejo, California, Valeant employs 3,767 people globally.
| Contact Details: |
| One Enterprise |
| Aliso Viejo |
| California |
| 92656 |
| United States of America |
| Tel: | 1.949.461.6000 |
| Fax: | 1.949.461.6609 |
| Email: | |
| WWW: | www.valeant.com/
|
|
Loading...
|
Recent Publications by Valeant Pharmaceuticals International: |  |
Recent patents on nucleoside and nucleotide inhibitors for HCV.
Hepatitis C virus (HCV) infection is a leading cause of liver diseases... | 22nd February, 2008
| Drug Discovery, Valeant Pharmaceuticals International, 3300 Hyland Avenue,
| Recent Pat Antiinfect Drug Discov. 2006 Nov;1(3):323-31.
|
Conversion of viramidine to ribavirin in vivo by adenosine deaminase and its inhibition by 2'-deoxycoformycin.
Previously we reported that viramidine is a prodrug of ribavirin and that... | 5th May, 2006
| Drug Discovery and Development, Valeant Pharmaceuticals International,
| Antivir Chem Chemother. 2006;17(1):33-9.
|
Parallel synthesis of 5-cyano-6-aryl-2-thiouracil derivatives as inhibitors for hepatitis C viral NS5B RNA-dependent RNA polymerase.
From random screening of our compound libraries, we identified a hit... | 4th May, 2006
| Valeant Pharmaceuticals International, 3300 Hyland Avenue Costa Mesa, CA
| Bioorg Chem. 2006 Feb;34(1):26-38. Epub 2005 Dec 19.
DOI Direct Link |
Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir.
The pharmacokinetics of pradefovir and adefovir,... | 28th April, 2006
| Valeant Pharmaceuticals International, 3300 Hyland Avenue, Costa Mesa, CA
| J Clin Pharmacol. 2005 Nov;45(11):1250-8.
DOI Direct Link |
Solid-phase synthesis of 5'-deoxy-5'-amino-clitocine analogues.
Several 6-substituted-amino-5'-deoxy-5'-amino-clitocine analogues were... | 4th April, 2006
| Department of Medicinal Chemistry, Valeant Pharmaceuticals International,
| Nucleosides Nucleotides Nucleic Acids. 2006;25(1):61-72.
|
→View more Valeant Pharmaceuticals International research publications. |
Press Releases on Valeant Pharmaceuticals International:
|
 |
| Reportlinker Adds Alzheimer's and Parkinson's Diseases - A Global Update of Market Trends & Opportunities |
18th November, 2009 |
Reportlinker |
NEW YORK, Nov. 18 /PRNewswire/ --
Reportlinker.com announces that a new market research report is available in its catalogue.
Alzheimer's and Parkinson's Diseases - A Global Update of Market
|
| Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease (AASLD) Annual Meeting |
3rd November, 2009 |
Valeant Pharmaceuticals International |
ALISO VIEJO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX) today announced that results from the week-72 analysis for its Phase IIb dose-finding clinical trial for
|
| Valeant Pharmaceuticals Reports Third Quarter Financial Results |
2nd November, 2009 |
Valeant Pharmaceuticals International |
ALISO VIEJO, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced third quarter financial results for 2009.
"Valeant continues to perform
|
| Valeant to Acquire Polish Products |
30th October, 2009 |
Valeant Pharmaceuticals International |
ALISO VIEJO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has agreed to acquire the rights to several prescription and cosmetic
|
| Valeant Pharmaceuticals to Announce 2009 Third Quarter Results on November 2, 2009 |
23rd October, 2009 |
Valeant Pharmaceuticals International |
ALISO VIEJO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that it will host a conference call and a live Internet webcast along with a
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 482 times since April 2007, the link to the organisation's website has been followed 70 times Recent Search Terms used to find this page: valeant vision ca | valeant pharmaceuticals international vision | valeant pharmaceuticals 2009 pdf | . Search for more companies in Aliso Viejo Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Valeant Pharmaceuticals International |
